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Until now, in various parts of the world,
no consensus has been reached with regard
to the treatment of acute mania. Con-
trolled clinical trials have at last pro-
vided irrefutable evidence for the effec-
tiveness of lithium, which had long been
used alone, as well as that of divalproate
or its derivatives and, to a lesser extent,
carbamazepine (1). In Europe, haloperi-
dol is still the reference compound used
in clinical trials while it has never been
officially approved in the treatment of
mania. In the USA, lithium, divalproate,
or second-generation-antipsychotics can
be prescribed as first-line treatments. As
dopamine was reported to be involved
in the pathophysiology of mania in the
1970s and as changes in dopaminergic
neurotransmission have consistently been
reported in bipolar disorders (BDs), the
question of the antimanic properties of
antidopaminergic drugs such as antipsy-
chotics is a fair one (2).
In Europe, lithium remains the first-line
medication, whereas divalproate and atyp-
ical antipsychotic agents are mainly used
as second-line treatments. Yet, manic inpa-
tients are frequently released from hospi-
tals while on neuroleptics or antipsychotics
even in the absence of psychotic symp-
toms or aggressive behavior (3). Although
both types of medications (antipsychotics,
mood stabilizer agents, and/or anticon-
vulsants) have proved their effectiveness
in the management of mania by reduc-
ing the mania scores overall, they do
not reduce all manic symptoms with
the same intensity. The British Associa-
tion of Psychopharmacology (BAP) guide-
lines reports that, in placebo-controlled
trials, the atypical antipsychotics used in
monotherapy, including aripiprazole, have
been shown to be effective in the treatment
of acute manic or mixed episodes (4). Fac-
torial approaches to mania have all shown
that since there are several clinical sub-
types of mania, several clusters of manic
symptoms can be identified. Antipsychotic
and mood stabilizer agents and/or anticon-
vulsants do not appear to have equivalent
effects on each of these identifiable clus-
ters of symptoms, especially on psychotic
features. We think that it is vitally impor-
tant for future clinical trials conducted in
mania treatment to focus on the treat-
ment effects using a factorial approach and
an appropriate methodological structure.
This question highlights the uncertainty
surrounding manic episodes, namely their
predominant mood or psychotic nature.
The Europeans consider mania to be
more of a mood episode and prefer lithium
as first-line treatment, whereas the Ameri-
cans believe that psychotic symptoms dom-
inate and widely use antipsychotic agents.
However, according to the clinical trials
currently available, even though antipsy-
chotic agents are certainly effective in
reducing the scores on the mania scales, it
is not clear whether they can be considered
purely as antimanic treatments. Nowa-
days, there is no clear consensus regard-
ing mania treatment. The question as to
whether mood stabilizer agents such as
lithium or anticonvulsants (even a com-
bination of both) or antipsychotic agents
should preferably be used as first-line treat-
ment of mania remains unanswered and
neither the American nor the European
guidelines provide an entirely satisfactory
answer to this crucial question. Indeed,
these two classes can have a somewhat dif-
ferent impact on the underlying symptoms
of mania (1). Both therapeutic strategies
are feasible and effective (5).
With regard to the American approach
(6), three classes of compounds are used
as first-line chemotherapy in the manage-
ment of mania: lithium, sodium dival-
proate, and antipsychotic agents. In case
of severe and purely manic or of mixed
episode, the APA advocates the use of a
combination of lithium and an antipsy-
chotic or lithium and sodium dival-
proate. Monotherapy using one of these
three compounds (lithium, sodium dival-
proate, or an antipsychotic) is recom-
mended for less severe episodes. Atypi-
cal antipsychotics (olanzapine and risperi-
done) are preferably used compared to typ-
ical antipsychotics due to their better safety
profile. Carbamazepine or oxcarbazepine is
used only as second-line treatment option.
Finally, clozapine is restricted to refractory
mania. In case of psychotic mania or com-
bined episodes, the APA recommends the
use of antipsychotic treatment. The 2nd
edition of the APA guideline for BDs issued
in 2010 do not modify its recommen-
dation regarding the treatment of acute
mania.
The recommendations for the man-
agement of acute mania remain largely
unchanged in Canada. Lithium, valproate,
and several atypical antipsychotic agents
are first-line treatments for acute mania.
Monotherapy with asenapine, paliperidone
extended release (ER), and divalproex ER
have been recently considered as first-line
options, as well as adjunctive asenapine (7).
1http://guidance.nice.org.uk/
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For APA, the severity of the manic
episode is the main criterion for treat-
ment decision; on the other hand, for the
National Institute for Health and Clini-
cal Excellence (NICE)1, the past history
of effective antimanic therapy is impor-
tant while the World Federation of Societies
of Biological Psychiatry (WFSBP)2 empha-
sizes the clinical classification of the type of
mania as an important criterion.
By contrast, in Europe, lithium remains
the reference compound as first-line treat-
ment. There are no clear European consen-
sus recommendations regarding the treat-
ment of mania. Sodium divalproate is
usually considered as a second-line treat-
ment in case of lithium contraindication
or intolerance. Tohen et al. (8) have car-
ried out a meta-analysis focusing on BD
treatments. They have found figures close
to 90% of use of typical antipsychotics in
the treatment of bipolar patients. These
figures are undoubtedly associated with
the acute onset of mania and the frequent
need to obtain adequate and quick seda-
tion, and, even in some patients, chemical
restraint. Sedation is a property of many
psychotropic drugs. It can be defined as a
decrease in psychomotor and cognitive per-
formances. Many of the classical neurolep-
tics were extremely sedative and sedation
came to be recognized either as adverse or
positive (9). In the classification of Delay
and Deniker, sleepiness, an extreme seda-
tive effect, is categorized as a side-effect.
However, in a more recent classification,
the sedative effect is considered to be a
major therapeutic effect. Atypical antipsy-
chotics are considerably less sedative than
typical antipsychotics while maintaining
equivalent or greater antipsychotic activity
meaning that sedation is not a prerequisite
in antimanic effect (10). Sedation is now
increasingly considered as an adverse effect,
which should be avoided in manic patients.
The use of typical neuroleptics in the
treatment of mania is not devoid of risk and
may expose the patient to adverse events.
Some authors have pointed out that they
could be responsible for exacerbation of
the episode and, in the long-term, could
adversely affect the disease prognosis (11).
Indeed, conventional neuroleptics can trig-
ger mood swings, cause depression, and
promote the onset of rapid cycling. The
other major risk associated with the use
of conventional neuroleptics is the occur-
rence of acute or delayed extrapyramidal
side-effects in manic patients, even more
frequently than in schizophrenic patients.
These potentially serious side-effects also
expose the prescriber to poor patient com-
pliance and can, therefore, have a negative
impact upon long-term disease progno-
sis (12). Finally, conventional neuroleptics
can rarely trigger malignant neuroleptic
syndrome (13).
Atypical neuroleptics have proven their
efficacy in the treatment of mania in several
recent studies. They appear to act on differ-
ent clusters of manic symptoms including
psychotic symptoms as well as hyperactiv-
ity, agitation, speech, and thought disor-
ders (12). They provide some advantages
as compared to typical neuroleptics such
as a lower risk of triggering mood swings,
an improvement of depressive symptoms,
and a better tolerance as compared to con-
ventional neuroleptics, especially as regard
to neurological symptoms (14). They can
also be used in the treatment of subtypes of
mania that have generally a poor response
to mood stabilizer agents such as rapid
cycling or mixed states. Unlike the situation
in the European Union, these drugs can be
prescribed as first-line therapy in the USA
where they can be used as monotherapy
in moderate forms or prescribed concomi-
tantly with lithium or divalproate in more
severe or even mixed episodes.
A meta-analysis including 68 ran-
domized controlled trials systematically
reviewed from 1980 to 2010 (16,073 par-
ticipants) has compared any of the fol-
lowing pharmacological drugs at thera-
peutic dose range for the treatment of
acute mania in adults: aripiprazole, asenap-
ine, carbamazepine, valproate, gabapentin,
haloperidol, lamotrigine, lithium, olanza-
pine, quetiapine, risperidone, topiramate,
and ziprasidone (15). The main outcomes
were the mean changes of the mania rat-
ing scales and the number of patients who
dropped out of the allocated treatment
at 3 weeks. An intention-to-treat analy-
sis was performed. Overall, antipsychotic
drugs were significantly more effective than
mood stabilizers. Risperidone, olanzapine,
and haloperidol should be considered as
the best options for the treatment of manic
episodes. This meta-analysis is in agree-
ment with a previous one (16) focus-
ing mainly on second-generation antipsy-
chotic monotherapy in acute mania but
in this latter study there was no compari-
son with classical antipsychotics. Aripipra-
zole has shown higher levels of response
and tolerability (less sedative) as compared
to haloperidol in the treatment of acute
manic episodes. At week 12, significantly
more patients taking aripiprazole (49.7%)
were in response and receiving therapy
compared with those taking haloperidol
(28.4%; P < 0.001). Continuation rates
differed markedly between treatments
(week 12: aripiprazole, 50.9%; haloperi-
dol, 29.1%). Extrapyramidal adverse events
were more frequent with haloperidol than
aripiprazole (62.7 vs. 24.0%) (17).
CONCLUSION
There is still no clear consensus regard-
ing the treatment of mania. Although the
North Americans have established and reg-
ularly updated guidelines related to the
management of mania, the same cannot be
said in Europe.
Excluding treatments that have not
proved effectiveness in methodologically
validated trials, two classes of treatments
have shown effectiveness: mood stabilizer
agents and/or anticonvulsants (such as
lithium, divalproate, or carbamazepine)
and antipsychotics (typicals or atypi-
cals). Among all antipsychotics, aripipra-
zole seems the most interesting compound
although its use leads to gastrointesti-
nal disturbances and movement disor-
ders. Comparative trials using other com-
pounds than haloperidol and lithium are
scarce, drawing conclusions about the use
of aripiprazole as a first-line or second-line
monotherapy treatment would be prema-
ture (18).
In the USA, lithium, divalproate, or
antipsychotics can be used as first choice
treatment. In Europe, lithium is still con-
sidered as first-line therapy whilst dival-
proate and atypical antipsychotics are used
only as second-line treatment. Conven-
tional antipsychotics, which should no
longer be recommended in the treatment
2http://www.wfsbp.org/activities/wfsbp-treatment-guidelines.html
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of mania, given their low safety profile, are
still widely used in Europe.
However, antipsychotic and mood sta-
bilizer agents do not seem to have the
same effects on each of the clusters of
manic symptoms, especially on mood or
psychotic clusters. In the future, clinical
trials may focus on this important ques-
tion using an appropriate methodological
design. However, from the standpoint of
the clinical trials currently available, even
though antipsychotic agents are certainly
effective in reducing the overall scores on
the mania scales, whether they can be con-
sidered real antimanic treatment remains
an unanswered question.
Even if all atypical antipsychotics do
appear to have a potential role in the
treatment of BD, especially during manic
episodes, it would be erroneous to consider
all antipsychotics as real antimanic drugs
(11). A “gold standard” antimanic therapy
would effectively manage all sorts of manic
symptoms while having a good safety pro-
file. Therefore to date for the authors, the
atypical antipsychotics of the “third gener-
ation”as aripiprazole which is a partial ago-
nist at the dopaminergic receptor level (19)
and very easy to use depending on the wide
large of posology, seems to be a real anti-
manic drug even if there is no difference
with lithium in the controlled clinical trials
(18). Aripiprazole therefore, is a significant
player in the current portfolio of antimanic
pharmacological treatments (20).
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